Kalaris Therapeutics (NASDAQ:KLRS) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Kalaris Therapeutics (NASDAQ:KLRS) from a hold rating to a sell rating in a research note released on Sunday,Wall Street Zen reports.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. TD Cowen initiated coverage on shares of Kalaris Therapeutics in a report on Monday, June 15th. They issued a “buy” rating for the company. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.75.

Kalaris Therapeutics Price Performance

Shares of KLRS opened at $3.38 on Friday. The company has a 50-day simple moving average of $4.04 and a two-hundred day simple moving average of $5.35. The firm has a market capitalization of $80.48 million, a PE ratio of -1.67 and a beta of 0.22. Kalaris Therapeutics has a one year low of $3.03 and a one year high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its earnings results on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. Analysts expect that Kalaris Therapeutics will post -1.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Pale Fire Capital SE bought a new position in Kalaris Therapeutics during the second quarter valued at approximately $161,000. Velan Capital Investment Management LP grew its position in Kalaris Therapeutics by 38.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock worth $102,000 after purchasing an additional 7,000 shares during the period. Sigma Planning Corp bought a new stake in Kalaris Therapeutics in the 2nd quarter worth approximately $41,000. Stonepine Capital Management LLC purchased a new stake in Kalaris Therapeutics during the 2nd quarter valued at $122,597. Finally, ADAR1 Capital Management LLC purchased a new stake in Kalaris Therapeutics during the 2nd quarter valued at $407,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.